Panel Discussion: Leveraging Early Strategies to Mitigate Clinical Toxicity in TCE Therapeutics
- Exploring design strategies to decouple cytokine production from therapeutic ability to bypass dose-limiting toxicities like CRS without compromising efficacy
- Deep diving into how tumor cells evade detection through antigen escape and the development of next-generation engagers designed to maintain long-term pressure on cold tumors
- Determining the optimal level of antigen expression required for clinical success